Prof. Johnson Stanslas

Brief Biography:

Johnson Stanslas obtained his PhD in the field of Cancer Pharmacology from the University of Nottingham, United Kingdom. He carried out his doctoral research under the supervision of Prof Malcolm Stevens. Dr Stanslas’s field of expertise is Pharmacology and Therapeutics. He is actively involved in the discovery and preclinical development of new anticancer, antiinflammatory (for allergic asthma), antiviral (antidengue) and antimalarial agents. He is the leader of the research group ‘Cancer Research and Drug Discovery (CRDD)’. To date he has been successful in discovering lead anticancer molecules for the treatment of breast, prostate and colon cancers. His research also extends to efficacy and toxicity studies of cytotoxic and molecular targeted agents in cancer patients with the intention of translating the laboratory findings to the clinic for improvement of cancer management. Translational research in neuroscience, particularly in personalising drugs for Parkinson’s Diseases and stroke is currently being actively pursued via the Neuroscience Cluster of Faculty of Medicine and Health Sciences, Universiti Putra Malaysia. He frequently evaluates local and international grant proposals. He has been a reviewer for many international journals of diverse fields. He is a member of the American Society for Pharmacology and Experimental Therapeutics (ASPET), American Association for Cancer Research (AACR), British Association for Cancer Research (BACR), European Association for Cancer Research (EACR) and Malaysian Oncological Society (MOS).

Academic positions:

1. Associate Professor in Pharmacology and Therapeutics at the Department of Medicine.

2. Research Associate at the Laboratory of Natural Products Discovery, Institute of Bioscience

Research interests:

* Pharmacology and Therapeutics
* Cancer Research specialising in Cancer Pharmacology
* Drug Discovery and Development – anticancer, antiviral (antidengue), antimalaria, antiasthma
* Pharmaceutical studies of natural products

Any other information:

Membership of Professional Organisations
1. American Society for Pharmacology and Experimental Therapeutics (ASPET)
2. American Association for Cancer Research (AACR)
3. European Association for Cancer Research (EACR)
4. British Association for Cancer Research (BACR)
5. Malaysian Oncological Society (Life Member)

Journal Reviewer
British Journal of Pharmacology

* Journal of Pharmacy and Pharmacology (frequent)
* Anticancer drugs
* Journal of Molecular and Celluar Endocrinology
* Iranian Journal of Pharmacology and Therapeutics
* Pharmaceutical Biology
* Journal of Ethnopharmacology (frequent)
* Journal of Natural Products (frequent)
* Planta Medica
* Phytochemistry
* Process Biochemistry
* Biochimie
* Medicinal Chemistry
* Redox report
* Journal of Cancer Research and Experimental Oncology
* Malaysian Journal of Medicine and Health Sciences
* Malaysian Journal of Medicine
* Letters in Drug Design & Discovery

What I think of the idea behind WebmedCentral:

It is an excellent and daring move to expedite publications. Presently, the average waiting period is just too long! I believe this will bring about a drastic change in time taken for publication of articles from all over the world.